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progression
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Samer Al-Saad1,4 & Lill-Tove Busund1,4
The role of steroid hormones in carcinogenesis of the prostate is to some extent unraveled thorough 
the effect of androgen deprivation therapy on prostate cancer (PCa) progression. Other members 
of the steroid hormone family, such as progesterone, are also implicated in PCa, but progesterone’s 
role remains undefined. This study aimed to examine the distribution of progesterone receptor 
isoforms (PGRA, PGRB) in PCa tissue and their association with clinical endpoints. This was conducted 
retrospectively by collecting radical prostatectomy specimens from 535 patients. Tissue was analyzed 
using tissue microarray, where representative tumor areas were carefully selected. Protein expression 
was evaluated through immunohistochemistry, in stromal and epithelial tissue. Associations between 
receptor expression and clinical data were considered using statistical survival analyses. Herein, we 
discovered a solely stromal PGRA- and a stromal and epithelial PGRB expression. Further, a high 
PGRB expression in tumor tissue was associated with an unfavorable prognosis in both univariate and 
multivariate analyses: Biochemical failure (HR: 2.0, 95% CI: 1.45–2.76, p < 0.001) and clinical failure 
(HR: 2.5, 95% CI: 1.29–4.85, p = 0.006). These findings are in agreement with our previous investigation 
on pan-PGR, indicating that the observed negative effect of PGR is represented by PGRB.
With worldwide incidence- and mortality rates of estimated 1.600 000 cases and 366 000 deaths annually, pros-
tate cancer (PCa) has been one of the most common cancers affecting males for decades1. Improved treatment 
strategies with drugs such as the new generation hormonal therapies, enzalutamide and abiraterone, has led to an 
increase in survival rates over the past years2,3. However, the nature of PCa remains a predicament for clinicians 
worldwide. The behavior of PCa has a broad specter, ranging from microscopic, well-differentiated tumors that 
remain indolent, to aggressive, high-grade tumors that eventually metastasize and result in morbidity and death. 
In addition, the heterogenous architecture of the tumors represent an impediment in the search for prognostic 
markers4. With limited progress in the development of prognostic markers, a great challenge remains in sepa-
rating those in need of radical treatment from those with a disease that will never become clinically significant.
Steroid hormones constitute a large family of hormones, all originating from cholesterol. These hormones 
and their precursors are primarily synthesized and metabolized in the adrenal glands and gonads of men and 
women5. They exert their functions either by binding their respective receptors and thereby initiating specific 
receptor–protein- and receptor–DNA interactions, or as substrates for further metabolism to other steroid hor-
mones5. In PCa, steroid hormones are considered tumor promoting factors. The proliferative effect has mainly 
been accredited to the androgens and the oncogenic role of the androgen receptor (AR) in tumor development, 
demonstrated by the effectiveness of androgen-deprivation therapy (ADT) on metastatic disease6. However, the 
PCa inevitably progresses despite of such treatment and becomes what today is known as “castration-resistant” 
prostate cancer (CRPC).
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Progesterone is a steroid hormone which, in addition to being an intermediate step in the steroid hormone 
synthesis pathway, is well known for its important role in female reproductive organs5. Essential functions in male 
physiology have also been acknowledged7. Progesterone binds and stimulates the progesterone receptor (PGR) 
which exists in two isoforms, PGRA (94 kD) and PGRB (114 kD). Both receptors are transcribed from a single 
gene, separated only by additional 164 amino acids found in the upstream N-terminal region of PGRB. Despite 
these small differences, this region renders the PGRB with an extra activating function8 and evidence that the 
transcriptional activity of ligand bound PGRB is superior to that of PGRA has been presented9. Further, the iso-
forms are regulated by different estrogen receptor (ER)-inducible promotors and have their own response genes, 
mediating the wide spectrum of physiological effects of progesterone with little overlap9,10.
A role of the PGRs in tumorigenesis is now established in several malignancies. In breast cancer, PGR is 
regarded as a surrogate marker for ERα activity, due to the direct ERα mediated upregulation of the gene encod-
ing PGR and the subsequent co-localization of the two receptors11. Its function in breast cancer development, 
however, remains unestablished, although the theory of an individual contribution by the PGR isoforms to malig-
nant development is receiving attention12,13. Indeed, the presence of the PGRs has been confirmed in several other 
malignancies including endometrial cancer14, PCa15–20, lung cancer21 and astrocytomas22, although not necessar-
ily separating between the two receptor isoforms. Altogether, this indicates the PGRs’ involvement in numerous 
biological processes throughout the human body and a broad spectrum of tissue specific receptor functions.
In a previous study, we described a negative effect on PCa outcome for patients with a high pan-PGR expres-
sion in tumor epithelial cells (TE). To further elucidate the significance of the PGRs in PCa, we systematically 
assessed both the stromal and epithelial expression of the two receptor isoforms, PGRA and PGRB, and evaluated 
their association with clinical outcomes in a large cohort of 535 PCa patients.
Materials and Methods
Patients and tissue data. This study includes tumor tissue and complete follow up data from 535 patients 
who underwent radical prostatectomy as initial PCa treatment. The material was collected retrospectively in the 
period 1995–2005 from the Departments of Pathology at the University Hospital of Northern Norway, Tromso 
(n = 248), St. Olav’s Hospital, Trondheim (n = 228), and Nordland Hospital, Bodo (n = 59). A total of 136 patients, 
of an original cohort of 671, were excluded from the study. Reasons for exclusion were: (1) radiotherapy to the 
pelvic region prior to surgery, (2) other malignancies within 5 years prior to the PCa diagnosis, (3) inadequate 
paraffin-embedded tissue blocks, (4) lack of clinical follow-up data or (5) due to hormonal therapy prior to or at 
the time of the prostatectomy. Demographic and clinical data were acquired from medical records. All prostate 
specimens were histologically re-evaluated and re-staged according to the 2010 TNM classification system23,24 by 
an experienced pathologist (ER). The tumors were further graded according to the modified Gleason grading sys-
tem25,26. All patient data (Table 1) were registered in a SPSS data file and de-identified. Patient outcome data were 
collected until the last follow up date or patient death. Median follow-up time was 150 (range 18–245) months 
at the last patient update in December 2015. Detailed description of the cohort has been published previously27.
Microarray construction. Tissue microarrays (TMAs) were constructed for the analysis of immunohisto-
chemical (IHC) staining expression. For each case, a pathologist (ER) identified and marked representative areas 
of the prostate specimens with tumor epithelial cells (TE), tumor associated stromal cells (TS), normal epithelial 
cells (NE), normal stromal cells (NS), in addition to areas with benign prostate hyperplasia (H) and prostate 
intraepithelial neoplasia (PIN). From each of these areas, cores were sampled from each donor block in order to 
construct TMA blocks. Prostate cores from 20 patients without any history of malignancy were used as controls.
The TMAs were assembled using a tissue-arraying instrument (Beecher Instruments, Silver Springs, MD, 
USA). A 0.6 mm diameter needle was used to harvest cores from the marked tissue areas from the correspond-
ing formalin-fixed paraffin-embedded tissue blocks. The samples were inserted into an empty recipient paraffin 
block according to a predefined coordinate pattern. To include all core samples, twelve tissue array blocks were 
constructed. Multiple 4 μm sections were cut with a Micron microtome (HM355S), affixed to glass slides. The 
detailed methodology has been previously reported28.
Immunohistochemistry. The following primary antibodies were chosen in order to detect expression of 
PGRA and PGRB: Novocastra anti-human PGR (clone:16, cat # NCL-L-PGR-312) mouse monoclonal antibody, 
directed against the A isoform of the human PGR. An antibody acknowledged by the American Society of Clinical 
Oncology as a well validated antibody for evaluating the PGR in breast cancer using IHC29 (Supplementary 
Data 1). ThermoFisher anti-progesterone receptor (clone: hPRa2, cat # MA5-12642) mouse monoclonal antibody, 
directed against the B isoform of the PGR, validated by the manufacturer (Supplementary Data 2). We sought 
to validate the applied antibodies in-house prior to submissions. However, no PGR isoform-specific siRNA’s or 
transfected overexpressed lysates that could be used with the applied antibodies were commercially available. 
Additionally, the close molecular weight of the two receptor isoforms makes antibody validation challenging. 
According to the manufacturer (Novocastra) of the PGRA antibody, western blotting would detect both isoforms 
(PGRA and PGRB) and is thus not a suitable method for validation of the antibody. The manufacturer further 
describes that the reason IHC only detects the A isoform might be the result of the epitope being inaccessible in 
the folded B form of the PGR. To control the antibodies specificity, we performed staining of negative and positive 
tissue controls prior to the IHC procedures on the PCa cohort. Additionally, staining control was performed by 
removing the primary antibody during IHC procedure. Slides from multi-organ TMA blocks were used to verify 
staining specificity in each antibody optimization run. Samples from normal endometrium and normal brain 
tissue were included as positive and negative tissue control for PGRA and PGRB respectively (Fig. 1). Of note, 
an antibody directed against the PGRA isoform (cat # MA5-12658) from same company (ThermoFisher) as the 
applied PGRB antibody was initially attempted. However, the staining was unspecific and the experiment failed.
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All TMA and control bocks required to be freshly sectioned for obtaining higher level of sensitivity. After 
overnight incubation of section slides at 60°, staining was performed with benchmark-ultra auto-immunostainer 
(Ventana). Slides were deparaffinized on the system with EZ Prep buffer for 3 cycles. A heat-induced pretreatment 
method was used in standard Cell Conditioning 1 (CC1) buffer at 95 °C with 64 (PGRA) and 48 (PGRB) min 
incubation time. The primary antibody was loaded at 1:25 (PGRA) and 1:50 (PGRB) dilution and was incubated 
for 60 min. The immune complexes were visualized with the optiView DAB Detection Kit (Ventana, # 760–700), 
followed by 4 (PGRA) and 8 (PGRB) minutes of amplification. Slides were counterstained with hematoxylin II 
Characteristics










Age 0.24 0.038 0.40
≤65 357 67 77 64 94 98
>65 178 33 70 59 91 98
pT-stage <0.001 <0.001 0.001
pT2 374 70 83 73 97 99
pT3a 114 21 61 45 87 98
pT3b 47 9 43 22 74 90
pN-stage <0.001 <0.001 <0.001
NX 264 49 79 68 96 99
N0 268 50 72 58 91 97
N1 3 1 0 0 33 67
Preop. PSA <0.001 0.029 0.003
PSA ≤ 10 308 57 81 68 95 99
PSA > 10 221 42 68 54 89 97
Missing 6 1
Gleason grade group <0.001 <0.001 <0.001
1 (3 + 3) 183 34 83 70 98 99
2 (3 + 4) 219 41 77 68 94 99
3 (4 + 3) 81 15 70 47 90 96
4 (4 + 4) 17 3 58 28 86 94
5 (≥9) 35 7 37 29 65 91
Tumor size <0.001 0.002 0.09
≤20 mm 250 47 83 70 96 99
>20 mm 285 53 68 55 90 97
PNI <0.001 <0.001 <0.001
No 401 75 80 70 96 99
Yes 134 25 60 41 83 95
PSM 0.049 0.20 0.84
No 249 47 80 66 96 98
Yes 286 53 70 59 90 98
Circumferrent PSM <0.001 <0.001 0.022
No 381 71 82 70 96 99
Yes 154 29 57 44 85 96
Apical PSM 0.063 0.43 0.13
No 325 61 74 58 92 98
Yes 210 39 77 68 93 99
LVI <0.001 <0.001 <0.001
No 492 92 77 64 95 99
Yes 43 8 47 39 70 90
Surgical procedure 0.47 0.31 0.96
Retropubic 435 81 77 63 92 98
Perineal 100 19 68 58 95 99
Table 1. Patient characteristics and clinicopathological variables in 535 prostate cancer patients (univariate 
analyses; log-rank test). Significant p-values in bold (threshold p ≤ 0.05). Patient characteristics and 
clinicopathological variables in 535 prostate cancer patients (univariate analyses; log-rank test). Significant 
p-values in bold (threshold p ≤ 0.05). Abbreviations: EFS = Event free survival; BF = Biochemical failure; 
CF = Clinical failure; PCD = Prostate cancer death; PSA = Prostate specific antigen; PNI = Perineural 
infiltration; PSM = Positive surgical margin, LVI = Lymphovascular infiltration.
www.nature.com/scientificreports/
4SCieNTifiC REPoRTS |  (2018) 8:11358  | DOI:10.1038/s41598-018-29520-5
Figure 1. Immunohistochemical staining for progesterone receptor A and B. Representative pictures of 
immunohistochemical staining for progesterone receptor A and B (PGRA and PGRB) expression in tissue 
microarray cores from prostate cancer prostatectomy specimens in addition to positive and negative control 
tissue. Microscope pictures taken with 15x magnification. PGRA panel: (A) low and (B) high stromal PGRA 
expression in a normal tissue core, (C) low and (D) intermediate - high stromal PGRA expression in a tumor 
tissue core, (E) negative tissue control in normal human brain tissue (F) positive tissue control in normal 
human endometrial tissue. PGRB panel: (A) low epithelial PGRB expression and low – intermediate stromal 
PGRB expression in a normal tissue core, (B) high epithelial PGRB expression and intermediate – high stromal 
PGRB expression in normal tissue core, (C) low – intermediate epithelial PGRB expression and low stromal 
PGRB expression in tumor tissue core, (D) high epithelial and stromal PGRB expression in a tumor tissue 
core, (E) negative tissue control in normal human brain tissue (F) positive tissue control in normal human 
endometrial tissue.
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(Ventana, # 790-2208) and bluing reagent (Ventana, #760-2037). Details regarding IHC control experiments are 
attached in the Supplementary File, Fig. 4.
Scoring of Immunohistochemistry. All tissue samples were scored semi-quantitatively by two experi-
enced investigators (ER, MR) independent of each other and blinded to any pathological or clinical information. 
The scoring was done manually using paired light microscopes. A third party (TG) recorded the mutely signaled 
values as the scoring progressed. In case of discrepancy (score difference > 1), the slides were re-examined and a 
consensus reached. Consequently, all reported marker expressions are based on two separate evaluations of the 
tissue cores.
Marker expressions were then evaluated in all different PCa compartments: NE, NS, H, PIN, TE and TS. 
Overall, the staining density of receptors displayed greater variation than the staining intensity, thus density was 
the chosen parameter. The density of PGRA and PGRB in each tissue compartment was given a score between 
0–3, reflecting the percentage of positive cells in the examined compartment. The applied scoring system for 
both PGRA and PGRB is as listed: 0 = 0%, 1 = 1–25%, 2 = 26–50%, 3 = >50%. A core was scored as “missing” 
either if it was missing or considered of insufficient quality to score by both observers. There was a good scoring 
agreement between the two investigators (ER, MR) with a total intra-class correlation coefficient with absolute 
agreement (reliability coefficient, r) of 0.93 (95% CI: 0.92–0.94, p < 0.001). For each tissue compartment, the 
mean score was calculated and connected to the patient’s clinical and histopathological information. The scoring 
values were further dichotomized into low and high density. To secure reproducibility and after considering the 
p-value and patient distribution between the groups, the cut off was set at mean value: PGRA in TS ≤ 1,34, PGRB 
in TE ≤ 1,34, PGRB in TS ≤ 0,89.
Statistical methods. All statistical analyses were performed with SPSS, version 24 (SPSS Inc., Chicago, 
IL, USA). The IHC scoring values from each pathologist were compared for inter-observer reliability by use of 
a two-way random effect model with absolute agreement definition. Correlation analyses were conducted using 
Spearman´s rank correlation coefficient to assess the correlation between the PGR´s expression, the clinico-
pathological variables and other previously published, potential prognostic markers. A correlation coefficient (r) 
of 0.3–0.49 was considered a moderate to weak correlation, r of 0.5–0.69 moderate to strong and finally r ≥ 0,7 
as strong. In our material, only r > 0,3 was taken into consideration. The Wilcoxon signed ranks test was used to 
compare marker expression within the different PCa compartments. Univariate survival analysis was conducted 
using the Kaplan-Meier method with the log-rank test assessing the statistical significance between the survival 
curves of the model. The following end-points were considered in the survival analyses: (1) Biochemical failure 
(BF), (2) Clinical failure (CF) and (3) PCa death (PCD). BF was determined as prostate specific antigen (PSA) 
recurrence ≥0.4 ng/ml in a minimum of two different blood samples postoperatively30 and biochemical failure 
free survival (BFFS) was calculated from the date of surgery to the last follow up date for BF, which was the last 
date of a measured PSA. CF was defined as verified local symptomatic progression beyond cure and/or findings 
of metastases to bone, visceral organs or lymph nodes by CT, MR, bone scan or ultrasonography. Clinical failure 
free survival (CFFS) was calculated from the date of surgery to the last follow up date for CF, which was the last 
date without symptoms or any evidence of metastasis. PCD was defined as death caused by progressive and dis-
seminated CRPC and prostate cancer death free survival (PCDFS) was calculated from the date of surgery to the 
date of death. All significant variables from the univariate analysis were entered in the multivariate analysis using 
a backward stepwise Cox regression model with a probability for stepwise entry removal at 0.05 and 0.1, respec-
tively. We considered a p-value < 0.05 as statistically significant for all analyses. Presentations of the survival 
curves were terminated at 192 months due to less than 10% of patients at risk after this point.
Ethics. This study was approved by the Regional Committee for Medical and Health Research Ethics, REK 
Nord, project application 2009/1393. A mandatory re-approval was conducted January 2016. As this was a ret-
rospective study, where the majority of material was more than 10 years old, and most of the patients deceased, 
REK Nord considered written patient consent not necessary. All patients were made anonymous with each trial 
number. These numbers were initially linked to identity for only one purpose prior; to collect clinical informa-
tion. The Data Protection Official for Research (NSD) approved the assembly of the database. The reporting of 
clinicopathological variables, survival data and biomarker expressions was conducted in accordance with the 
REMARK guidelines31.
Data and material availability. A deidentified SPSS dataset including patient clinicopathological variables 
and marker expression variables is attached as a supplementary file.
Results
Patient characteristics. An overview of patient characteristics is presented in Table 1 and have previously 
been addressed in detail27. Median age at surgery was 62 years (range 47 to 76), the median PSA was 8.8 (range 
0.7–104) and the median tumor size was 20 mm (2.0–50). The prostatectomy was retropubic in 435 cases (81%) 
and perineal in 100 cases (19%). Post-operative hormonal therapy was given to 89 (17%) of the patients and 
post-operative radiation therapy to 103 (19%), either due to rising PSA values, persisting PSA or unfree surgical 
margins. At the last follow-up in 2015, 200 patients (37%) had experienced BF, 56 (11%) CF and 18 (3%) had died 
due to PCa.
PGRA and PGRB expression. PGRA expression was detected exclusively in stromal tissues and the stain-
ing was predominantly nuclear with a weaker cytoplasmic staining observed in some of the stained stromal 
cells. Expression of PGRB was located in both stromal and epithelial cells with a granular staining pattern in the 
nucleus. A weaker homogenous staining was also detected in the cytoplasm of a subgroup of both stromal and 
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epithelial cells. The same expression patterns were also detected in the healthy control specimens. The stained 
stromal cells appeared morphologically to be mainly smooth muscle cells and fibroblasts. For both markers, the 
IHC staining was detected in a majority of tissue cores, this included both normal and tumor tissue compart-
ments. Representative examples of PGRA and PGRB IHC staining in the PCa cohort are visualized in Fig. 1 and 
examples of PGRA and PGRB staining in TMA cores from healthy prostate tissue are visualized in Supplementary 
Fig. 3.
Of the 535 patients, 432 (81%) of the patients had TE and 454 patients (85%) TS that could be examined for 
PGRB and PGRA expression. Further, only 15 (3%) of the patients had a complete absence of stromal PGRA 
expression. Regarding PGRB, 96 (18%) of the patients had no epithelial expression and 102 (19%) patients had 
no stromal expression. A total of 69 (13%) patients had a combined negative stromal and epithelial expression 
of PGRB and 12 (2%) had neither PGRA nor PGRB expression. It was a significantly higher PGRA stromal cell 
density compared to PGRB in all stromal compartments (p < 0.001). As for PGRB, there was a significantly higher 
density of the receptor in epithelial tissue, compared to the surrounding stromal tissue (p < 0.001). Finally, no sig-
nificant difference in density was detected between PGRA expression in TS compared to NS, nor to PGRB expres-
sion in TE or TS compared to NE and NS respectively. We did not detect any moderate or strong association 
between either PGRA nor PGRB and the clinicopathological variables listed in Table 1. There was a strong and 
significant correlation between PGRB in TE and TS (r = 0,82, p < 0,001), but no other significant correlation at a 
moderate or strong level was detected between the investigated markers and other previously published markers.
Univariate analysis. Results from univariate analyses of clinicopathological variables and molecular mark-
ers and their association to the outcome measures (BF, CF, PCD) are presented in Tables 1, 2 and Fig. 2. A sig-
nificant decrease in both BFFS and CFFS was observed for patients with a high PGRB expression in TE (BFFS: 
p < 0.001, CFFS: p = 0.006) and TS (BFFS: p = 0.034, CFFS: p = 0.034). No additional prognostic value was evi-
dent when merging PGRB expression in TE and TS. There was no significant association detected between PGRA 
expression levels in stromal cells and outcome measures (Supplementary Fig. 1). The same trend was observed 
when considering the results throughout the different pathological centers, however without significant levels for 
each subgroup (Supplementary Fig. 2).
Multivariate analysis. Multivariate analyses are presented in Table 3. When assessed alongside with the 
clinicopathological variables, a high PGRB expression in TE remained an independent prognostic marker for 
both BF (HR: 2.0, 95% CI: 1.45–2.76, p < 0.001) and CF (HR: 2.5, 95% CI: 1.29–4.85, p = 0.006). Regarding BF, a 
positive circumferential surgical margin, PNI, Gleason grade group (GGG) 3 (3 + 4) and 4 (4 + 3), preoperative 
PSA, and pT-stage 3b were additional independent prognosticators. Regarding CF, high PGRB expression in TE 
remained an independent marker alongside with age ≥60, LVI and Gleason grade group 1 through 5. PGRB in 
TS did not reach statistical significance in multivariate analyses.
Discussion
Herein, we demonstrated a wide distribution of the PGR proteins in both stromal and epithelial PCa tissues, 
which is in agreement with our previous report18. In this study, both isoforms of the PGR, PGRA and PGRB, 
where assessed. In our cohort, the PGRA expression was exclusive to stromal tissue, whereas PGRB expression 
was observed in both stromal and epithelial tissues. Further, we identified a significant decrease in BFFS and 
CFFS for patients with a high level of PGRB in TE with as much as 2.5 times increase in risk of CF. No such asso-
ciations were observed for the PGRA. Hence, it is likely to assume that our previously observed impact of PGR 
expression in TE was indeed effectuated by the PGRB isoform18.
To our knowledge, Yu et al. is the only research group15,32 that has recently investigated PGR and its isoforms 
in PCa, including the various tissue compartments. Whereas our study detected PGRB expression in 81% (432 
of 523 patients) of TE from the investigated patients, conflicting data regarding epithelial expression has been 
presented by Yu et al.15, detecting PGRB only in a subset of stromal cells in a small cohort of 27 prostatectomy 
Marker expression
Patients BF CF
n % Events (n) 5-year EFS (%) 10-year EFS (%) p Events (n) 10 – year EFS (%) p
PGRB TE <0.001 0.006
Low 226 42 65 82 71 15 95
High 206 39 99 66 51 30 90
Missing 103 19
PGRB TS 0.034 0.034
Low 321 60 133 77 64 27 94
High 133 25 61 64 53 21 89
Missing 81 15
Table 2. Significant results from univariate analyses of PGRB. Expression of progesterone receptor B (PGRB) in 
tumor epithelial cells (TE) and tumor associated stromal cells (TS) of prostate cancer and its relation to clinical 
endpoints. The table presents the significant reduction in event-free survival (EFS) time for patients with high 
levels of PGRB in TE or TS (univariate analyses; log-rank test). Significant p-values in bold (threshold p ≤ 0.05). 
Abbreviations: BF = Biochemical failure; CF = Clinical failure.
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cases. In their more recent work with IHC on TMAs from a larger cohort (n = 194), using a pan-PGR antibody, a 
great distribution of stromal PGR was described. The epithelial distribution of PGR was however not addressed33 
and thus difficult to compare with our work. Using cell line studies, Yu et al.33,34 also demonstrated a favorable 
role of both PGR isoforms in regulating the stromal environment. This is, however, in contrast with our results 
where high PGRB levels in TS was associated with a worse prognosis in univariate analyses. This was however not 
statistically significant in multivariate analyses.
Earlier results supporting our observation of a negative role of the PGR in PCa have been published16,17, yet 
several previous publications are also in disagreement regarding PGR tissue expression, though most do not differ 
between the isoforms. Results regarding PGR’s presence in stromal tissue appears univocal15–20. The epithelial PGR 
distribution is however debated. While a total absence has been described by some groups15,19, other groups in 
addition to ours, clearly detect its presence16–18,20. Thus, the PGRs physiological function in the normal prostate and 
their role in PCa development is not yet defined. Interestingly, a selection of commercially available PGR specific 
antibodies have been compared in an earlier paper, in which a great variance in receptor expression was observed 
between the different antibodies35. All applied antibodies detected PGRA, but many failed to recognize PGRB in 
formalin fixed tissue. Moreover, the PGRA specificity of our applied antibody is supported by these investigations. 
These discrepancies may explain why some previous studies failed to recognize PGR in epithelial cells.
PGRA and PGRB have to a greater extent been investigated in female reproductive organs than the prostate, 
as outlined in the review by Scarpin and colleagues36. Herein, the observation by Mote et al.12,37 of a 1:1 receptor 
Figure 2. Kaplan-Meier curves presenting significant results from univariate analyses. The Kaplan-Meier 
curves demonstrate a high and low progesterone receptor B (PGRB) expression level dichotomized at mean 
value and the association with patient outcome. A reduction in biochemical failure free survival (BFFS) and 
clinical failure free survival (CFFS) was demonstrated for patients with a high expression of PGRB in both 
tumor epithelial cells (TE) (A,B) and tumor associated stromal cells (TS) (C,D). Significant p-value in bold 
(threshold p ≤ 0.05).
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ratio of PGRA/PGRB in healthy female reproductive tissue is described and it is hypothesized that the majority 
of progesterone targeting tissue in humans have an expression profile not deviating far from this. A disruption of 
this receptor homogeneity has been demonstrated in different cancers. Mote et al.12 observed a PGRA predomi-
nance in human breast cancer lesions compared to the 1:1 ratio in healthy breast tissue. However, in endometrial 
cancer, the loss of equilibrium in PGRA/PGRB ratio and the subsequent predominance of either of the isoforms 
was observed as an early event in tumorigenesis14. In our material, there is also evidence of receptor disequi-
librium as presented in the results section. In brief, this indicates that a receptor expression imbalance would 
result in changes in progesterone signaling in hormone-dependent tissues. This is supported by a recent study by 
Singhal et al.13 demonstrating that breast cancer tumors expressing higher levels of either PGRA or PGRB had 
different gene expression profiles and inhabited the ability to reprogram ER signaling in an independent manner. 
It would be of great interest to further assess the PGR isoform ratio in this prostate cancer cohort. However, con-
sidering the semi-quantitative scoring system applied herein, this is not a sufficiently precise method for assessing 
receptor ratio expression. A more appropriate approach for the future would be to assess the ratio after a full 
digital quantification of positive cells. Other groups have also applied immunofluorescence for the visualization 
of co-localization and ratio-assessment12,37, which is also an approach to consider for the future.
Several reflections must be made when considering how a high PGRB expression level can have a negative 
prognostic effect in PCa. Co-expression of steroid hormone receptors in hormone dependent cancers is preva-
lent, and recent discoveries have implicated a considerable interaction between these receptors. This could be 










pT3a 1.4 0.93–2.10 0.105
pT3b 2.3 1.40–3.83 0.001
Preop PSA 0.021 NS
PSA ≤ 10 1.0
PSA > 10 1.5 1.06–2.07
Missing
Gleason grade group 0.058 0.013
1 (3 + 3) 1.0 1.0
2 (3 + 4) 1.3 0.87–1.95 0.203 3.3 1.01–10.01 0.035
3 (4 + 3) 1.7 1.05–2.75 0.032 5.8 1.80–18.50 0.003
4 (4 + 4) 2.7 1.30–5.50 0.008 6.3 1.37–29.00 0.018
5 (>9) 1.6 0.90–2.10 0.148 7.9 2.28–27.44 0.001












PGRB in TE <0.001 0.006
Low 1.0 1.0
High 2.0 1.45–2.76 2.5 1.29–4.85
Table 3. Results from multivariate analyzes. Results from Cox regression analysis (backward stepwise 
model) displaying progesterone receptor B and the other remaining independent prognosticators for patient 
outcome in prostate cancer patients (n = 535), significant p-values in bold (threshold p ≤ 0.05). Abbreviations: 
PGRB = Progesterone receptor B; BF = Biochemical failure; CF = Clinical failure; HR = Hazard ratio; 
CI = Confidence interval; PSA = Prostate specific antigen; PNI = Perineural infiltration; PSM = Positive 
surgical margin, LVI = Lymphovascular infiltration; TE = Tumor epithelial cells; NE = Not entered; NS = Not 
significant.
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self13,38–41. In PCa, the glucocorticoid receptor (GR) has been associated with tumor progression and enzaluta-
mide resistance by reactivation of a selection of AR-target genes38,39. The PGR is, like the GR, similar to AR with 
a high sequence homology in the DNA-binding domain42, indicating a transferability of this theory to the PGRB. 
Results from breast cancer models indicate that the PGRs can modulate ER function and target gene activity 
through several mechanism, one being modulation of chromatin binding40,41. Similar mechanisms of interplay 
may exist between the PGRs and other steroid hormone receptors in PCa, but this warrants further investigation. 
Coregulatory proteins influence the expression and function of steroid hormone receptors. Aberrant expression 
of coregulatory proteins belonging to the p160 steroid receptor coactivator (SRC) family that are associated with 
modulation of the PGRs, such as SRC-2 and SCR-3, have been implicated in PCa and other hormone dependent 
malignancies43,44.
In summary, it is highly likely that our observed negative prognostic effect of a high PGRB expression in 
PCa is just the tip of the iceberg in a complex steroid hormone interplay in PCa development. To this date, the 
prognostic and therapeutic value of PGRA and PGRB in PCa remains undefined. However, the lack of available 
prognostic biomarkers, in addition to the progression of PCa to CRPC despite the emerging strategies targeting 
steroid hormones, makes this a subject for further investigation. Mifepristone is a compound with antagonistic 
abilities towards PGRs, AR in addition to the GR45. So far, the inhibitory effect of mifepristone on the GR in CRPC 
has been explored by Isikbay et al. reporting inhibition of CRPC growth and delayed progression in pre-clinical 
models39. This effect was however not observed in a small phase II clinical trial46. Alas, none of these studies 
considered expression of the PGR and its isoforms. Studies considering PGR inhibition in earlier stages of PCa is 
also lacking. There is however an ongoing phase I/II clinical trial investigating the effect of the anti-progestin ona-
pristone in patients with CRPC and confirmed PGR expression47. This study may shed more light into this issue.
Major strengths of this study are our large, multicenter cohort (n = 535), the long follow-up time (mean 12.4 
years), our precise and separate focus on stromal and epithelial tissue compartments in addition to our attempt to 
standardize cut-off values. However, this study approach has its natural limitations given that it only investigates 
associations between specific protein-expressions in PCa tissue and patient outcomes. It explains little about the 
underlying mechanisms regarding a potential oncogenic role of PGRB in PCa. Hence, at this stage, it can only be 
considered exploratory and hypothesis generating. Consequently, this study would greatly benefit from additional 
functional studies investigating the migratory and invasive potential of PGRB expressing cells. Another valuable 
approach for the future would be the investigation of the transcriptome regulated by the PGR isoforms in both 
epithelial and stromal cells, and also different cellular processes regulated by the different PGRs. Other natural 
limitations in this study are due to the nature of PCa and the subsequent low number of events (CF, and PCD) 
despite the long follow-up in our cohort that challenges the statistical analyses.
Conclusion
Herein, we present the distribution of PGRA and PGRB expression in stromal and epithelial PCa tissue in a large 
cohort (n = 535) of primary PCas. We depict how PGRB in TE emerge as a strong independent predictor of 
PCa recurrence. No association with clinical endpoints was discovered for PGRA. This indicates that differences 
in PGR isoform expression may provide tumors with distinctive prognostic and hormone-responsive features, 
underscoring the importance of isoform specific evaluation of the tumors PGR status. It also raises the question 
whether treatment strategies targeting specific PGR isoforms in PCa might be beneficial. However, due to con-
flicting results in the current literature, further exploration is essential before the clinical value of the PGRB status 
is resolved.
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